Definition
Galunisertib (development code LY2157299) is an oral, small‑molecule inhibitor of the transforming growth factor‑beta (TGF‑β) type I receptor kinase (also known as activin receptor‑like kinase 5, ALK5). It is classified as an investigational therapeutic agent primarily studied in oncology and fibrotic disease clinical trials.
Overview
Galunisertib was discovered and initially developed by Eli Lilly and Company. The compound functions by selectively binding to the ATP‑binding pocket of ALK5, thereby blocking downstream SMAD2/3 phosphorylation and attenuating TGF‑β‑mediated cellular processes such as proliferation, migration, and extracellular matrix production. Preclinical studies demonstrated antitumor activity in several cancer models, leading to multiple phase I and phase II clinical investigations. Reported indications in trial protocols have included glioblastoma, pancreatic ductal adenocarcinoma, hepatocellular carcinoma, and certain fibrotic disorders. As of the latest publicly available data, galunisertib has not received regulatory approval from the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).
Etymology / Origin
The name “galunisertib” follows a naming convention commonly used for small‑molecule kinase inhibitors, where the suffix “‑sertib” denotes a selective inhibitor of a signaling pathway. The prefix “galuni‑” does not correspond to a standard linguistic root but likely reflects an internal code or branding choice by the developing company rather than an etymologically derived term.
Characteristics
| Aspect | Information |
|---|---|
| Chemical class | Pyrrolopyrimidine‑based kinase inhibitor (exact chemical structure publicly disclosed in patent literature) |
| Molecular formula | Reported as C₂₁H₂₃F₃N₈O₅ in some patent filings; however, precise confirmation from peer‑reviewed sources is limited. |
| Mechanism of action | Competitive inhibition of the ATP‑binding site of TGF‑β type I receptor (ALK5), preventing SMAD2/3 activation. |
| Administration | Oral tablets; dosing regimens in trials have varied (e.g., 150 mg twice daily in a 14‑day on/14‑day off schedule). |
| Pharmacokinetics | Reported oral bioavailability and a terminal half‑life of approximately 10–12 hours in early‑phase studies; metabolized primarily by CYP3A4. Precise parameters may differ across study populations. |
| Safety profile | Common adverse events observed in trials included fatigue, nausea, and mild hematologic changes; no definitive dose‑limiting toxicity pattern has been universally established. |
| Regulatory status | Investigational; not approved for any indication as of the most recent regulatory updates (2024). |
Related Topics
- Transforming Growth Factor‑Beta (TGF‑β) Signaling – a multifunctional cytokine pathway implicated in cancer progression, immune regulation, and tissue fibrosis.
- ALK5 (Activin Receptor‑Like Kinase 5) Inhibitors – a class of agents targeting the TGF‑β type I receptor, including other experimental compounds such as fresolimumab (a monoclonal antibody) and LY3200882.
- Oncologic Clinical Trials – phase I/II studies evaluating galunisertib in combination with standard chemotherapies, immune checkpoint inhibitors, or radiotherapy.
- Anti‑Fibrotic Therapeutics – research into TGF‑β pathway blockade as a strategy to treat pulmonary, hepatic, and renal fibrosis.
Note: Information regarding the exact chemical composition, pharmacokinetic parameters, and trial outcomes is based on publicly disclosed data up to 2024. Where details are limited or not corroborated by peer‑reviewed literature, the entry reflects the current state of verified knowledge.